Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Observational

ATI Evidence-based Guide Investigating Medical and Preventative Services

NCT04050319 · tracked via the Priya Life Science USA tracker
Sponsor
ATI Holdings, LLC
Phase
Observational
Started
2026-04-23
Last updated
2026-05-04

Condition(s) studied

Sport Medicine

Investigational drug(s) / intervention(s)

Screening and diagnosis if injured

Screening and diagnosis if injured: Athletic Training and Physical Therapy

Study summary

To use existing standard-of-care documentation in a sports medicine electronic medical record (EMR) to evaluate patient characteristics, interventions delivered, utilization management, and clinical outcomes in routine sports medicine care, in order to generate evidence to improve clinical effectiveness and quality of care.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Care setting and timeframe: Received sports medicine services at ATI Physical Therapy, with documentation available in the ATI Sports Medicine EMR, on or after January 1, 2018, through the date of data extraction. Age range: Sports participants including middle school, high school and collegiate aged including adolescents through young adults that have been documented in the EMR. Record availability: Have an EMR record that includes the minimum data elements necessary to address the study objectives (e.g., episode identifiers/dates sufficient to define an episode of care, diagnosis/body region, utilization variables, and at least one routinely collected outcome measure when applicable to the specific analysis). Standard-of-care data: Data were collected as part of routine clinical care/documentation prior to and independent of this research study. Exclusion Criteria: The record is outside the eligible timeframe or does not reflect sports medicine care at ATI. The record is a duplicate or cannot be reliably linked within the data source to a single episode/patient for analysis. The record lacks the minimum necessary variables required for the specific analysis (e.g., missing episode dates needed to define utilization metrics; missing baseline/discharge outcome for analyses requiring change scores). The data are corrupted, internally inconsistent (e.g., impossible dates), or otherwise unsuitable for analysis after standard data cleaning. The record cannot be adequately coded/de-identified for analysis and reporting under the study's privacy/confidentiality procedures.

Primary outcome measure(s)

  • Numerical Rating Scale (NRS) — Baseline (Day 1 at Evaluation), throughout patient's episode of care asked each visit, on average up to 12 weeks
    Subjective; Patients rate pain on a scale from 0 (no pain) to 10 (worst pain imaginable).
  • Single Assessment Numeric Evaluation (SANE) — Administered at initial evaluation, and every 4th visit for the patient's episode of care (on average 12 weeks).
    Subjective, Patient-perceived overall function or pain related to a specific condition compared to pre-injury. 0% (least possible) to 100% (most possible/normal)

Trial sites (1)

FacilityCityRegionStatus
ATI Downers Grove Illinois

More ATI Holdings, LLC trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04050319 on ClinicalTrials.gov ↗ ← All trials in the USA